GenKOre announced a strategic collaboration with Revvity's Gene Delivery franchise (formerly known as SIRION Biotech GmbH), a specialist in viral vector-based gene delivery for gene and cell therapy. This research collaboration aims to develop effective gene therapy treatments for ocular disorders, specifically targeting Leber Congenital Amaurosis 10 (LCA10) and Usher Syndrome Type 2A (USH2A). GenKOre will leverage its proprietary TaRGET platform (tiny nuclease, augment RNA-based genome editing technology) to create in vivo gene therapies for LCA10 and USH2A.

Unlike the widely known CRISPR-Cas9, the TaRGET platform allows the entire editing module to be delivered using a single adeno-associated virus (AAV) vector, offering a more efficient and streamlined approach to gene-editing therapy. objectives of the Collaboration: Development of Superior Gene Therapies: Combining GenKOre's TaRGET technology with Revvity's advanced AAV capsids to develop in vivo gene-editing therapy with enhanced efficacy and safety profiles. Expanding Therapeutic Applications: Validating the applicability of the TaRGET platform for in vivo therapy and extending its utility to a broader spectrum of rare diseases.

Advancing Gene Editing Technology: Leveraging the combined expertise of both companies to address unmet medical needs and pioneer new frontiers in genomic medicine. If the strategic research collaboration is successful, GenKOre has the opportunity to expand the agreement to a full development and commercialization license.